Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Inclusion Criteria: * AJCC stage IIC, III, IV or recurrent cutaneous melanoma * Adequate bone marrow function * Age less than or equal to 21 years of age at diagnosis * Adequate liver and kidney function Exclusion Criteria: * Prior Therapy with dacarbazine or temozolomide * Patients who have uncontrolled infection * Patients with autoimmune hepatitis * Patients who have a history of depression or other psychiatric diseases requiring hospitalization * Patients taking systemic corticosteroids including oral steroids (i.e. prednisone, dexamethasone) or topical steroid creams/ointments. Steroid containing inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast-agent related allergic reaction will be permitted. * Patients with hypersensitivity reaction to non-pegylated interferon α-2b are not eligible for study * Patients with diabetes mellitus not adequately controlled with medication * Patients with hypo- or hyperthyroidism not adequately controlled with medication. * Patients with a history of myocardial infarction, severe or unstable angina, or severe peripheral vascular disease.